Furthermore, somatic mutations in MALAT1 have been so far identified in women with breast cancer (luminal-type) [136] and its depletion in luminal cells from ER+ tumors has been reported to dramatically restrain tumor cells’ proliferation [137]. Here, MALAT1 is linked to breast carcinoma.